Driven by the human genome project, and research in the area of AIDS, geriatric diseases, neurosciences, and drug development (antiviral, antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents is projected to reach $32.5 billion by 2012. The shift towards proteomics from genomics in the post-genome-project research period is forecast to benefit protein related product markets in the upcoming years.
San Jose, California (PRWEB) November 13, 2008 -- Reagents used in biotechnology are complex chemical compounds used in a range of biotech related areas including biochemistry, cell biology, molecular biology, immunology, protein chemistry, pharmacology, and biotechnology research. The market is dependent to a large extent on applications of biotechnology instrumentation. With the focus shifting from the gene towards the protein, disciplines such as molecular biology and protein synthesis continue to gain wide attention from the academic and commercial sectors alike. However, highly automated instrumentation is expected to temper the use of reagents. The whole spectrum of biotech, medical, and biological technologies has facilitated researchers to develop highly specialized human biological products with significant therapeutic and commercial potential. Yet, the most significant value provided by these technologies may not be limited to their end products. Greater value will be the insights provided into the disease processes.
As stated by the recent report published by Global Industry Analysts Inc, United States and Europe collectively account for a share of nearly 65% of the global biotechnology reagents market estimated in 2008. Driven by its extensive use in large-scale commercial applicati
Copyright©2008 Vocus, Inc.
All rights reserved